
Kepler upgrades the German biomedical systems manufacturer Stratec SBSG.DE to "buy" from "hold", as it expects demand to recover
The broker points to a slump in demand since the Covid pandemic, during which the market for molecular diagnostics was saturated
The stock value has dropped 83 percent from its peak value in 2021, Kepler adds
However, the analyst says that "the business is clearly viable", "the recovery of industrial demand is a question of time" and "leverage is not a concern"
Therefore, Kepler views Stratec's stock as undervalued
Stratec shares are up 4.65%, making Stratec on of the top gainers on the .SDAXI index